Health Technology Assessment

Program co-ordinator: Prof. Zoltán Kaló

For more information: https://semmelweis.hu/phd/en/doktori-iskolak-en/gyogyszertudomanyok-en/

1. Economic evaluation of health technologies

Topics:

• Health technology assessment: definition, domains and applicability in health policy decisions
• Importance and classification of full economic evaluations
• Main types of economic models and recommendations for their use
• Steps of economic evaluation
• Decision rule for economic evaluations
• Transferability of health technology assessment
• Value judgment of health technologies based on traditional and extended value criteria
• Methodology of budget impact analysis and importance on health policy decisions

Recommended reading (English):

• Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Fourth edition 2015. Oxford University Press
• Bodrogi J, Kaló Z. Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development. Br J Pharmacol. 2010. 159(7):1367-73.
• Kovács S, Németh B, Erdősi D, Brodszky V, Boncz I, Kaló Z, Zemplényi A. Should Hungary Pay More for a QALY Gain than Higher-Income Western European Countries? Appl Health Econ Health Policy, 2022. 20(3). 291-303.
• Nagy B, Campbell JD, Kaló Z. The Role of Modelling in Economic Evaluations in Health Care. Eötvös University Press, Budapest, 2019. (https://www.eltereader.hu/media/2019/07/Nagy_Balazs_NT_WEB.pdf)
• Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, Orlewska E, Penna P, Rodriguez Barrios JM, Shau WY. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014. 17(1):5-14.
• Garattini L, van de Vooren K. Budget impact analysis in economic evaluation: a proposal for a clearer definition. Eur J Health Econ. 2011. 12(6):499-502.
• Inotai A, Jakab I, Brixner D, Campbell J, Hawkins N, Kristensen L, Charokopou M, Mountian I, Szegvari B, Kaló Z. Proposal for Capturing Patient Experience through Extended Value Frameworks of Health Technologies. J Manag Care Spec Pharm. 2021. 27(7). 936-947.
• Lakdawalla DN, Doshi JA, Garrison LP Jr, Phelps CE, Basu A, Danzon PM. Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3]. Value Health. 2018. 21(2):131-139
• Jakab I, Whittington MD, Franklin E, Raiola S, Campbell JD, Kaló Z, McQueen RB. Patient and Payer Preferences for Additional Value Criteria. Frontiers in Pharmacology. 2021. 12:690021.
• Jakab I, Németh B, Elezbawy B, Karadayı MA, Tozan H, Aydın S, Shen J, Kaló Z. Potential Criteria for Frameworks to Support the Evaluation of Innovative Medicines in Upper-Middle-Income Countries – A Systematic Literature Review on Value Frameworks and Multi-Criteria Decision Analyses. Frontiers in Pharmacology, 2020. 11. 1203.
• Németh B, Goettsch W, Kristensen FB, Pinyazhko O, Huić M, Tesař T, Atanasijevic D, Lipska I, Kaló Z. The transferability of health technology assessment – the European perspective with focus on Central and Eastern European countries, Expert Rev Pharmacoecon Outcomes Res. 2020. 20. 4. 321–329.
• Drummond M, Augustovski F, Kaló Z, Yang BM, Pichon-Riviere A, Bae EZ, Kamal-Bahl S. Challenges faced in transferring economic evaluations to middle income countries. Int J Technol Assess Health Care. 2015. 31. 6. 442-8.

Recommended courses related to the topic

• Applied health economics (Dr. Inotai András, Dr. Kaló Zoltán, Dr. Nagy Balázs)
• Health economic aspects of pharmaceutical R&D decisions
• Prerecorded webinars to each topic are available upon request

2. Evidence synthesis related to the assessment of health technologies

Topics:

1. Definition and importance of scientific evidence in health care and health technology assessment
2. Classification of scientific evidence (according to study design és publication types), aspects and barriers of their ranking
3. Evidence generation methods (analysis of primary data, qualitative and quantitative evidence synthesis methods), definition and relationship of systematic literature review and meta-analysis
4. Detailed methodology of systematic literature review (conditions and main steps of systematic review) and presentation of current international methodological guidelines (PRISMA, Cochrane Handbook)
5. Applicability of systematic literature review, including advantages and limitations
6. Main types of meta-analyises
7. Methods for the description and evaluation of heterogeneity in meta-analyses
8. Prevention and assessment of potential biases in meta-analyses
9. Conditions of network meta-analyses and their evaluation

 Recommended reading (English):

• Cochrane Handbook for Systematic Reviews: https://training.cochrane.org/handbook/current
• PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) statement: https://www.prisma-statement.org/
• Evidence Synthesis for Decision Making in Healthcare – Nicky J. Welton, Alexander J. Sutton, Nicola Cooper, Keith R. Abrams, A. E. Ades, 2012, John Wiley & Sons Ltd

Recommended courses related to the topic

• Systematic literature review & meta-analysis: a practical approach (Dr. Vokó Zoltán)
• Systematic review and meta-analysis in science and clinical practice I. (Dr. Hegyi Péter)